在复发性复发性多发性硬化症中计划减少ocrelizumab的剂量:单中心观察性研究
Trung Dang Quoc Tran1,2, Leanne Hall1, Clare Heal1
1College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia.
BMJ neurology open
|June 24, 2024
概括
在复发性复发性多发性硬化症 (RRMS) 患者中,每6个月降低奥克雷利祖马布剂量至300mg,维持了治疗疗效和B细胞枯竭. 在这项观察性研究中,这种剂量降低策略没有显示出新的安全问题.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 奥克雷利祖马布有效治疗复发性复发性多发性硬化症 (RRMS).
- 在RRMS中B细胞枯竭的长期安全性尚未完全理解.
- 缺乏关于减少ocrelizumab剂量作为降低风险策略的数据.
研究的目的:
- 在RRMS患者中,每6个月将ocrelizumab剂量从600mg降低到300mg的有效性进行评估.
- 为了评估这种ocrelizumab剂量降低策略的安全性.
- 在剂量减少后分析复发率,残疾进展和MRI活动.
主要方法:
- 在单个神经病学服务中心进行观察性研究.
- 35例RRMS患者至少接受了一次减少剂量 (300毫克) 的ocrelizumab.
- 对复发,残疾进展,MRI病变,CD19+细胞计数和免疫球蛋白水平的分析.
主要成果:
- 在降低剂量的患者中没有观察到复发或新的MRI活性.
- 持续的CD19+B细胞枯竭得到维持 (≤0.05×10^9/L).
- 平均免疫球蛋白水平 (IgG,IgA,IgM) 保持稳定;没有出现新的安全问题.
结论:
- 将ocrelizumab剂量减少至每6个月300mg似乎保持了对RRMS新发炎性疾病活动的有效性.
- 需要进一步的随机试验来确认这些发现并评估长期的安全性.
- 降低剂量可能是对RRMS治疗ocrelizumab的可行的降低风险策略.
相关概念视频
01:01Dosage Regimen: Fixed Dose
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:28Dosage Regimens: Designs and Approaches
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...